4:19 PM
 | 
Dec 01, 2017
 |  BC Extra  |  Company News

Astellas acquires build-to-buy Mitobridge

Astellas Pharma Inc. (Tokyo:4503) exercised an exclusive option to acquire mitochondrial disorder company Mitobridge Inc. (Cambridge, Mass.) for $225 million up front and up to $225 million in milestones under an amended 2013 deal.

Created in 2012 by MPM Capital as Mitokyne...

Read the full 194 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >